FIG 1.

Overview of efficacy and treatment with rucaparib plus SG. (A) Duration of treatment and best overall response. Arrowhead denotes ongoing treatment as of the August 11, 2020, data cutoff date. (B) Change in tumor volume over time for each patient. Dotted line indicates the threshold for partial response (30% decrease from baseline). Because of the COVID-19 pandemic, SG was withheld after cycle 6 for patient 1. SG was then discontinued during cycle 11 at the patient's request. SG was withheld after cycle 4 for patient 4 because of the pandemic. BARD1, BRCA-associated ring domain protein 1; BRCA1, BRCA1 DNA repair associated; BRCA2, BRCA2 DNA repair associated; HRR, homologous recombination repair; OC, ovarian cancer; PARP, poly(ADP-ribose) polymerase; PD, progressive disease; PR, partial response; SD, stable disease; SG, sacituzumab govitecan; TNBC, triple-negative breast cancer; UC, urothelial cancer.